Maurie Markman, MD, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.
Back
The Moonlight Shift
The Moonlight Shift, with host Gina Mauro, features leading and early-career oncologists from the Tri-State corridor in peer-level conversations about where the field is going — and what it still has to work out.
The Moonlight Shift
Episodes
All
All
Joshua Richter, MD, joins The Moonlight Shift to discuss the remarkable evolution of multiple myeloma treatment.
Nicholas Hornstein, MD, PhD, discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and more.
In this episode of the Moonlight Shift, Jonathan Lee, MD, and Chinmay Jani, MD, dive into the ins and outs of oncology fellowship and training.
Paul Oberstein, MD, discusses results of the phase 3 RASolute 302 for daraxonrasib in pretreated metastatic pancreatic cancer.
Patrick Borgen, MD, built Brooklyn's breast cancer program from 47 patients to 8,000. Now he and Joshua Feinberg, MD, discuss what surgery looks like next.
Andrew Evens, DO, MBA, MSc, SVP, & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.
Herbert Lepor, MD, discusses NYU Langone's 1,000th focal cryotherapy procedure, Andre De Shields' case, and why prostate cancer treatment is at a turning point.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
5